AstraZeneca’s Lynparza (olaparib) Receives MHLW’s Orphan Drug Designation for BRCA-Mutated Metastatic Pancreatic Cancer

 AstraZeneca’s Lynparza (olaparib) Receives MHLW’s Orphan Drug Designation for BRCA-Mutated Metastatic Pancreatic Cancer

AstraZeneca’s Lynparza (olaparib) Receives MHLW’s Orphan Drug Designation for BRCA-Mutated Metastatic Pancreatic Cancer

Shots:

  • The ODD is based on P-III POLO study assessing Lynparza (300mg, bid) as maintenance monothx. vs PBO in 154 patients in a ratio (3:2) with gBRCAm metastatic PC without disease progression on 1L Pt. based CT
  • The P-III POLO study results: improvement in PFS (7.4 vs 3.8mos.); 47% reduction in disease progression; patients with measurable disease at baseline, responded patients (23% vs 12%); median duration of treatment in excess of 2yrs. (24.9 vs 3.7mos.); median OS (18.9 vs 18.1mos.)
  • Lynparza is a first-in-class PARP inhibitor acts by targeting DDR in cells/tumors harboring a deficiency in HRR (BRCA1& 2 mutation) and has received the US FDA’s approval in Dec’2019 with its ongoing regulatory reviews in the EU and other regulatory bodies

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: Twitter

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post